🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Happy to share our institutional analysis of NSCLC patients with germline EGFR mutations in JTO & JTO CRR with Xiuning Le MD PhD 🔸Majority Caucasian, non-smoking, females, with family history of lung cancer 🔸21/22 with “second-hit” EGFR somatic co-mutation (L858R in 50%). Tp53

SOOOO proud of our MD Anderson Cancer Center med onc star fellows Michael LaPelusa, MD, Kelsey Pan, MD, MPH, & Mir Lim presenting their research today on #crcsm day at ASCO #GI25 ! Future is looking bright with their brilliant minds to #endcancer !

Great data for pts w/ 2+ line met anal cancer for pembrolizumab+ficerafusp alfa (EGFR/TGFb bispecific) -ORR 29% & 41% 12-mo DFS=benefit in liver mets+pCR for exceptional responder ! Exciting signal as combination immuotherapy in anal cancer! MD Anderson Cancer Center #endcancer Bicara Therapeutics

👏👏👏 BREAKWATER ph3 trial shows improved ORR (61% vs 40%) w/ addition of enco+cetux to chemotherapy for pts with untreated BRAF V600E mCRC!!! further improving how we care for this pt population! Kudos to Scott Kopetz for leading this great effort 👏👏👏 MD Anderson Cancer Center #endcancer

Congrats Daniel Haldar for your ASCO #GI25 master class on where we are and where we are heading for cancer vaccines in MSS CRC - excited to see where you lead the field to #endcancer for our #crcsm pts in the years to come! MD Anderson Cancer Center

When (-) study is VERY informative for BRAF mut CRC! ORR w/enco+cetux+nivo in MSS BRAFV600E mCRC: NO prior BRAF inhibitor: 50% Prior BRAF inhibitor: 0% E+C+N will NOT be effective post BREAKWATER tx. 👏MD Anderson Cancer Center ⭐️onc fellow & UNC-Chapel Hill Tar Heel Kelsey Pan, MD, MPH !#GI25 #endcancer

Very grateful that those oncologists who inspire me to #endcancer also happen to be incredible humans! Thanks to all for coming out in SF to celebrate life and love! ❤️🌈 #GI25

Does site matter for #immunotherapy benefit in anal cancer? ⭐️McGovern Med School MS4 Arjun Peddireddy showed pts w/lymph node-only met disease may benefit most w/immunotherapy - PFS > 3x than w/ other visceral organs! #ancsm #endcancer MD Anderson Cancer Center mdpi.com/3218198 #mdpicancers

SO EXCITED to kick off our new Colorectal Med Onc section at MD Anderson Cancer Center w/an exciting retreat- such a wildly talented, brilliant, & fun group dedicated to excellence in caring for pts w/ #crcsm & cutting-edge research, inspired by the amazing PCR. LET'S GO TEAM!! #endcancer

👏Dr Arjun Peddireddy on your McGovern Med School graduation! Our MD Anderson Cancer Center team has been so proud to mentor you to 1st-author paper as a med student! We cite your findings to anal cancer pts getting immunotherapy! UVA IM Residency (UVAIMR) -you're getting a⭐️ #ancsm #endcancer

🌟 DOUBLING of OS for adding encorafenib + cetuximab to FOLFOX in frontline treatment for (MSS) BRAF V600E mCRC!! ‼️ Providers should be testing for BRAF V600E mutations ASAP upon diagnosis of met CRC to identify pts who may benefit from this regimen!! 🙏 Grateful to be a

❔ ctDNA detection is PROGNOSTIC for inferior outcomes following resection of stage III colon cancer, but is treating more aggressively better? ‼️ NO improvement in RFS by escalating treatment with a ctDNA-informed approach. Congrats to DYNAMIC-III study team for highly

🌟 proud mentor alert!! Mir Lim presenting her findings that complement activation signatures in CRC associate with BRAF V600E mutations and immune-suppressing myeloid cells - for CRC primary tumors and liver mets alike! Can we utilize this for design of new tx strategies in

“How are we acting like everything is just business as usual at ASCO this year?” Feeling very stricken by this simple question yet very empowered for doing the right thing at the ASCO LGBTQIA+ Community of Practice happening right now!!

Congrats to the most amazing Kelsey Pan, MD, MPH for her MD Anderson Cancer Center fellowship graduation. You are getting a ⭐️ Winship Cancer Institute of Emory University and such a privilege to mentor you and so excited to watch your 🌟 continue to shine to #endcancer for thoracic oncology pts in the years to come!!

Very happy to host you this past month as a visiting trainee, Supriya peshin - our GI Med Onc team at MD Anderson Cancer Center is always happy to help build rising stars like you who are the next generation of oncologists who will help to #endcancer!

Our GI Medical Oncology team at MD Anderson Cancer Center is hiring! We are committed to build up medical oncologists excelling in patient care & who will lead research efforts to #endcancer for #crcsm pts - & we are a very fun team to work with 😉 bit.ly/44cVHYs

👏 👏 congrats Prajnan Das, MD, MS, MPH on becoming our MD Anderson Cancer Center GI Rad Onc chair!! We are thrilled to work with you and your amazing team in the years to come to #endcancer for our patients with #crcsm and #ancsm !!